Rocket Pharmaceuticals (RCKT) Accumulated Expenses (2014 - 2026)

Rocket Pharmaceuticals has disclosed Accumulated Expenses across 13 years of filings, most recently posting $5.2 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $5.2 million, down 25.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.2 million (down 25.99% YoY), and the FY2025 annual result was $12.3 million, up 2.93% from the prior year.
• Accumulated Expenses came in at $5.2 million for Q1 2026 at Rocket Pharmaceuticals, down from $12.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $12.3 million in Q4 2025 to a low of $1.6 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $7.3 million (2024), against an average of $7.4 million.
• Across the five-year window, Accumulated Expenses jumped 1280.14% in 2022 and dropped 25.99% in 2026, its largest moves.
• Rocket Pharmaceuticals' Accumulated Expenses stood at $10.0 million in 2022, then declined by 0.76% to $9.9 million in 2023, then climbed by 20.28% to $11.9 million in 2024, then advanced by 2.93% to $12.3 million in 2025, then sank by 57.42% to $5.2 million in 2026.
• The last three Accumulated Expenses figures came in at $5.2 million (Q1 2026), $12.3 million (Q4 2025), and $11.4 million (Q3 2025), per Business Quant data.